Compare Nano Dimension Ltd - ADR (NNDM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nano Dimension Ltd - ADR vs BIO-TECHNE Corp — how do they compare? Nano Dimension Ltd - ADR trades at $1.51 (market cap $327.47M), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: BIO-TECHNE Corp is far larger — about 34.6× Nano Dimension Ltd - ADR's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Nano Dimension Ltd - ADR pays none. Which is the better fit depends on your goals.
| NNDM | TECH | |
|---|---|---|
Market Cap | $327.47M | $11.34B |
Sector | Technology | Health |
52-Week High | $2.14 | $72.48 |
52-Week Low | $1.21 | $43.31 |
Enterprise Value | -$77.38M | $11.36B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NNDM trades at $1.555, down 4.01% on the day, amid a bearish technical signal and negative cash flow. The company reported a net loss of $293.30M on $102.44M revenue in 2025, with a negative net income margin of 135.18%. Recent news highlights board changes, cost-saving initiatives, and a planned sale of MarkForged to Stratasys, aimed at reducing cash burn.
The outlook remains challenged by persistent losses and cash burn, though strategic divestitures may improve liquidity. Key risks include execution of turnaround plans and competitive pressures. Analyst sentiment is cautious given the financial performance and ongoing corporate restructuring.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
